Ultragenyx Files 8-K on Jan 7, Signals Upcoming Disclosure

TL;DR

**Ultragenyx filed a barebones 8-K on Jan 7, hinting at an upcoming material event.**

AI Summary

Ultragenyx Pharmaceutical Inc. filed an 8-K on January 7, 2024, indicating a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934. This filing, while not disclosing specific financial results or operational changes, signals that an event requiring disclosure occurred on January 7, 2024. For investors, this matters because 8-K filings often precede significant news, and while this one is sparse, it could be a precursor to an announcement about financial condition or other material events, impacting the stock's future performance.

Why It Matters

This 8-K indicates that Ultragenyx experienced an event requiring immediate disclosure on January 7, 2024, which could be a precursor to significant news impacting its stock price.

Risk Assessment

Risk Level: low — The filing itself is administrative and does not contain information that directly impacts the company's financial health or operations, thus posing a low immediate risk.

Analyst Insight

A smart investor would monitor Ultragenyx Pharmaceutical Inc. (RARE) closely for subsequent filings or press releases that would detail the specific event that triggered this 8-K, as this filing itself is a placeholder for future, more substantive news.

Key Players & Entities

• Ultragenyx Pharmaceutical Inc. (company) — the registrant filing the 8-K
• January 07, 2024 (date) — date of the earliest event reported
• 001-36276 (null) — Commission File Number
• RARE (null) — Trading Symbol on Nasdaq Global Select Market

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select

Filing Documents

• rare-20240107.htm (8-K) — 42KB
• rare-ex99_1.htm (EX-99.1) — 34KB
• img45776771_0.jpg (GRAPHIC) — 367KB
• img45776771_1.jpg (GRAPHIC) — 14KB
• 0000950170-24-002655.txt ( ) — 715KB
• rare-20240107.xsd (EX-101.SCH) — 23KB
• rare-20240107_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 7, 2024, Ultragenyx Pharmaceutical Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing preliminary unaudited fiscal year 2023 total revenue, revenue for Crysvita and revenue for Dojolvi, cash, cash equivalents and available-for-sale investments at 2023 fiscal year end, total 2024 revenue guidance, 2024 revenue guidance for Crysvita and Dojolvi, and expected 2024 net cash used in operations. The Company expects to report its full year results for the 2023 fiscal year in February 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 7, 2024 104 The cover page from the Company’s Current Report on Form 8-K dated January 7, 2024 formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: January 8, 2024 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy

View Full Filing

View this 8-K filing on SEC EDGAR